FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381136619> ?p ?o ?g. }

• W4381136619 abstract "Problems related to the limitations of chemotherapeutic treatments compel the pressing necessity to develop a drug-delivery system that will specifically target tumor cells and have minimal or no harmful effects on normal/healthy cells. This study aimed to comparatively evaluate the ability of chemically versus biologically synthesized site-specific selenium-silver bimetallic stabilized folic targeted nanoparticles (SeAgChPEGFA NPs) to efficiently deliver doxorubicin (DOX) in cervical cancer cells (HeLa). The NPs were synthesized using a coreduction method chemically using sodium borohydride and polyvinylpyrrolidone, and biologically using fenugreek seed extract. Moreover, the NPs from both methods of synthesis were stabilized and functionalized using carbodiimide and adsorptionreaction procedures. The drug/DOX-loaded nanocomplexes (NCs) were prepared via anadsorption and amide bonding reaction process between the co-polymer stabilized NPs and DOX. The bimetallic NPs and their DOX-loaded NCs were characterized using ultraviolet- visible (UV-vis) spectroscopy, Fourier-transform infrared spectroscopy (FTIR), transmission electron microscopy (TEM), and zeta Sizer. The drug release, loading, and encapsulation capabilities were evaluated in an in vitro environment. The effects of the synthesized NCs on cell viability and programmed cell death analysis were evaluated by means of the 3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay and a dual staining technique in selected human non-cancer and cancer cell lines (HEK293 and HeLa cells), respectively. The NPs and their drug-loaded NCs were successfully formulated and characterized. The successful synthesis of the NPs was initially validated by the reaction mixtures’ change in colour from cloudy to red-orange and subsequently from yellow-gold to orange-brown, signifying the formation of SeAg NPs and F-SeAg NPs, respectively. The UV- spectroscopy revealed that the SeAg NPs absorbance peaks were between 260 nm and 320 nm, while the FTIR verified the stabilization and functionalization of the NPs by revealing the presence of carbodiimide and amide bonds. All the resultant NPs and their drug-loaded NCs were shown asspherical withthe NPs appearing predominantly monodispersed and the NCs as groups. The sizes of the chemically and biosynthesized NPs ranged between 103.5 nm and 138.8 nm and that of the DOX-loaded NCs ranged between 154.9 nm and 158.7 nm respectively. The DOXloaded chemically- and biologically-synthesized NCs showed good stability with zeta measurements of 53.1 ± 2.3 mV and 57.4 ± 1.9 mV, respectively. The encapsulation efficiency (EE%) and drug loading (DL%) percentages of the chemically synthesized NCs were calculated to be 84% and 26%, respectively, while the percentages of the biosynthesized NCs were 87% and 22%, respectively. The cytotoxicity and anticancer activities of the BMNPs/NCsfrom both methods of synthesis were cell-specific and concentration-dependent. Overall, the encapsulation of DOX to the eco-friendly formulated BNPs enhanced the biocompatibility, bioavailability, and therapeutic effects ofthe drug in tumor cells, with limited harm to the healthy cells, thus showing promise as alternative delivery systems for targeted cancer treatment. The findings indicated that both the chemically synthesized and biosynthesized NPs showed great potential as anticancer drug-delivery modalities, with the biosynthesized SeAgChPEGFA@DOX NCs showing superior optical, surface charge stability, and drug encapsulation properties than the chemically synthesized SeAgChPEGFA@DOX NCs and free DOX. Moreover, among the studied synthesis methods, biosynthesis is reported to be eco-friendly and as a result the more ideal anticancer drug-delivery system with favourable features forfuture in vivo applications. Thus, future studies can encompass in vivo assessment of this eco-friendly system to further evaluate at a broader scale the bimetallic system’s efficacy and safety before using these NPs clinically." @default.
• W4381136619 created "2023-06-19" @default.
• W4381136619 creator A5046806932 @default.
• W4381136619 date "2023-06-19" @default.
• W4381136619 modified "2023-09-26" @default.
• W4381136619 title "The in vitro delivery of Doxorubicin using biosynthesized versus chemically synthesized stealth site-specific Bimetallic Selenium-silver nanoparticles" @default.
• W4381136619 doi "https://doi.org/10.51415/10321/4817" @default.
• W4381136619 hasPublicationYear "2023" @default.
• W4381136619 type Work @default.
• W4381136619 citedByCount "0" @default.
• W4381136619 crossrefType "dissertation" @default.
• W4381136619 hasAuthorship W4381136619A5046806932 @default.
• W4381136619 hasConcept C127413603 @default.
• W4381136619 hasConcept C13965031 @default.
• W4381136619 hasConcept C155672457 @default.
• W4381136619 hasConcept C160892712 @default.
• W4381136619 hasConcept C161790260 @default.
• W4381136619 hasConcept C171250308 @default.
• W4381136619 hasConcept C178790620 @default.
• W4381136619 hasConcept C185592680 @default.
• W4381136619 hasConcept C188027245 @default.
• W4381136619 hasConcept C192562407 @default.
• W4381136619 hasConcept C202751555 @default.
• W4381136619 hasConcept C21951064 @default.
• W4381136619 hasConcept C2775997276 @default.
• W4381136619 hasConcept C2777366897 @default.
• W4381136619 hasConcept C2779820397 @default.
• W4381136619 hasConcept C2780077769 @default.
• W4381136619 hasConcept C2780783641 @default.
• W4381136619 hasConcept C42360764 @default.
• W4381136619 hasConcept C43411465 @default.
• W4381136619 hasConcept C53227056 @default.
• W4381136619 hasConcept C55493867 @default.
• W4381136619 hasConceptScore W4381136619C127413603 @default.
• W4381136619 hasConceptScore W4381136619C13965031 @default.
• W4381136619 hasConceptScore W4381136619C155672457 @default.
• W4381136619 hasConceptScore W4381136619C160892712 @default.
• W4381136619 hasConceptScore W4381136619C161790260 @default.
• W4381136619 hasConceptScore W4381136619C171250308 @default.
• W4381136619 hasConceptScore W4381136619C178790620 @default.
• W4381136619 hasConceptScore W4381136619C185592680 @default.
• W4381136619 hasConceptScore W4381136619C188027245 @default.
• W4381136619 hasConceptScore W4381136619C192562407 @default.
• W4381136619 hasConceptScore W4381136619C202751555 @default.
• W4381136619 hasConceptScore W4381136619C21951064 @default.
• W4381136619 hasConceptScore W4381136619C2775997276 @default.
• W4381136619 hasConceptScore W4381136619C2777366897 @default.
• W4381136619 hasConceptScore W4381136619C2779820397 @default.
• W4381136619 hasConceptScore W4381136619C2780077769 @default.
• W4381136619 hasConceptScore W4381136619C2780783641 @default.
• W4381136619 hasConceptScore W4381136619C42360764 @default.
• W4381136619 hasConceptScore W4381136619C43411465 @default.
• W4381136619 hasConceptScore W4381136619C53227056 @default.
• W4381136619 hasConceptScore W4381136619C55493867 @default.
• W4381136619 hasLocation W43811366191 @default.
• W4381136619 hasOpenAccess W4381136619 @default.
• W4381136619 hasPrimaryLocation W43811366191 @default.
• W4381136619 hasRelatedWork W2074890984 @default.
• W4381136619 hasRelatedWork W2392909360 @default.
• W4381136619 hasRelatedWork W2962761150 @default.
• W4381136619 hasRelatedWork W3161467378 @default.
• W4381136619 hasRelatedWork W4212874734 @default.
• W4381136619 hasRelatedWork W4280603295 @default.
• W4381136619 hasRelatedWork W4324306065 @default.
• W4381136619 hasRelatedWork W4381665838 @default.
• W4381136619 hasRelatedWork W655950944 @default.
• W4381136619 hasRelatedWork W2801828268 @default.
• W4381136619 isParatext "false" @default.
• W4381136619 isRetracted "false" @default.
• W4381136619 workType "dissertation" @default.